UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
UroGen Pharma (Nasdaq: URGN) said the USPTO issued a Notice of Allowance for patent application 18/784,354 covering non-surgical treatment of recurrent low-grade intermediate-risk NMIBC using a thermally gelling mitomycin composition, supported by ENVISION and ATLAS trial data. If issued, the U.S. patent would expire in July 2044 for ZUSDURI and UGN-103.
How this was made
The 30-second read
Why it matters
The USPTO Notice of Allowance covers specific treatment methods for recurrent LG-IR-NMIBC without TURBT, supported by ENVISION and ATLAS trial data, and indicates an expected expiration in July 2044 once issued.
Market read
This is a company-specific IP durability update that can support valuation via reduced competitive risk, but it is not a clinical outcome or regulatory decision.
What to watch
Potential patent scope, prosecution risks, and whether competitors can design around the allowed claims could limit the practical value of the July 2044 expiration.
Background
UroGen’s ZUSDURI (mitomycin intravesical solution) uses its RTGel reverse-thermal hydrogel platform; UGN-103 is positioned as a next-generation program building on ZUSDURI.
Ticker impact
UroGen received a USPTO Notice of Allowance for a patent covering non-surgical treatment of recurrent LG-IR-NMIBC with ZUSDURI/UGN-103, expiring July 2044.
Moderately positive near-term sentiment, with limited immediate fundamentals impact until issuance and any subsequent regulatory/commercial milestones.
A Notice of Allowance is a meaningful IP milestone, but it is not the final issued patent and the article provides no new clinical, regulatory, or financial datapoints beyond the allowance and stated expiration.
Market effects
Reinforces the value of IP strategy around intravesical, non-surgical oncology formulations and RTGel-based delivery platforms.
Primarily US-focused due to USPTO action; limited direct regional spillover.
Supports global commercial confidence in ZUSDURI/UGN-103 IP, though the allowance is US-specific.
Counterpoint
A Notice of Allowance may not translate into an issued, enforceable patent without further prosecution, and the market may discount it versus clinical or FDA catalysts.
Key entities
- public_companyUroGen Pharma Ltd.
Nasdaq-listed biotech developing RTGel-based intravesical therapies, including ZUSDURI and investigational UGN-103.
- regulatorUSPTO
US Patent and Trademark Office issuing the Notice of Allowance for the patent application.
- productZUSDURI
FDA-approved mitomycin intravesical solution for recurrent LG-IR-NMIBC using RTGel delivery.
- investigational_programUGN-103
Investigational next-generation intravesical mitomycin program intended to reinforce and extend ZUSDURI’s profile.
